PDCD1 and cancer: A Phase I clinical trial is currently underway using crystalline Hafnium oxide nanoparticles that exhibit immune stimulating effects in addition to its radio-enhancing properties along with anti-PD1 for treatment of individuals suffering from any form of primary cancer and with lung or liver metastasis [169].